Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.46 |
| ▸ | APP | P05067 | 7/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24733039 | 1.00 | KMT2A (0.46) | KMT2AMEN1NPC1HIF1AAPP | |
| SCHEMBL29977534 | 0.84 | BACE1 (0.52) | KMT2AMEN1HIF1AAPPPDE5A | |
| SCHEMBL24733043 | 0.84 | BACE1 (0.52) | KMT2AMEN1HIF1AAPPPDE5A | |
| SCHEMBL24732902 | 0.83 | PDE5A (0.48) | KMT2AMEN1NPC1HIF1APDE5A | |
| SCHEMBL29809088 | 0.83 | PDE5A (0.48) | KMT2AMEN1NPC1HIF1APDE5A | |
| SCHEMBL13968056 | 0.82 | KMT2A (0.66) | KMT2AMEN1APPPDE5APOLB | |
| SCHEMBL30947352 | 0.80 | APP (0.47) | KMT2AAPPPDE5APOLBRAD52 | |
| SCHEMBL8114510 | 0.79 | BCHE (0.56) | KMT2AMEN1NPC1PDE5APOLB | |
| SCHEMBL5073659 | 0.79 | APP (0.48) | KMT2AMEN1NPC1APPPDE5A | |
| SCHEMBL8121604 | 0.78 | KMT2A (0.55) | KMT2AMEN1APPPDE5APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-05-09 | — | — | US | disclosed |
| CN-114805341-B | Aromatic heterocyclic compound, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TLR7, TLR1, TLR8 | KMT2A 2443/4885MEN1 2988/4885NPC1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.